Assessment of hepatic function in cystic fibrosis by lidocaine metabolism
| Autor: | Lawrence J. Sindel, Charles Hoff, David A. Gremse, Robert C. Boerth, David J. Wells |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Indocyanine Green Male medicine.medical_specialty Pancreatic disease Lidocaine Adolescent Cystic Fibrosis Gastroenterology Cystic fibrosis chemistry.chemical_compound Liver Function Tests Internal medicine medicine Humans Child Volume of distribution business.industry Dye Dilution Technique Blood flow medicine.disease Endocrinology chemistry Liver Case-Control Studies Pediatrics Perinatology and Child Health Female Liver function business Indocyanine green Drug metabolism medicine.drug Half-Life Liver Circulation |
| Zdroj: | Journal of pediatric gastroenterology and nutrition. 32(4) |
| ISSN: | 0277-2116 |
| Popis: | BACKGROUND To determine hepatic drug metabolism in patients with cystic fibrosis, as measured by monoethylglycinexylidide formation after lidocaine injection and indocyanine green (ICG) clearance. METHODS The following study is a case-control study, which included 19 patients with cystic fibrosis and 13 control subjects. Serum monoethylglycinexylidide concentration was measured after intravenous injection of 1 mg/kg (maximum, 50 mg) lidocaine. Indocyanine green (0.5 mg/kg) was injected concomitantly, and absorbance (805 nm) of serum was measured over time to determine its volume of distribution, serum half-life, and hepatic blood flow. RESULTS Monoethylglycinexylidide formation was decreased in patients with cystic fibrosis compared with controls (39.4+/-16.9 microg/L versus 70.3+/-45.7 microg/L, mean +/- SD, respectively, P < 0.02). Indocyanine green half-life (4.6+/-2.7 min versus 3.0+/-1.0 min), volume of distribution (8.6+/-5.5 L versus 8.3+/-3.4 L), and hepatic blood flow (10.9+/-5.9 ml x kg(-1) x min(-1) versus 7.4+/-2.0 ml x kg(-1) x min(-1)) were similar in both groups. CONCLUSION Monoethylglycinexylidide formation after lidocaine injection is impaired in patients with cystic fibrosis. This impairment may have clinical implications when using hepatically metabolized medications in patients with cystic fibrosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text